Emerging New Standard of Care for HER2 Breast Cancer

Dr. Stephen Malamud, Mount Sinai
Save to PDF By
Stephen Malamud, MD, associate professor of medicine at the Icahn School of Medicine at Mount Sinai in New York, explains the differences in efficacy for various CDK drugs.

Dr. Malamud describes some significant improvements in progression-free survival in patients with breast cancer who have received targeted therapies.

Featured Video

Emerging New Standard of Care for HER2 Breast Cancer

Emerging New Standard of Care for HER2 Breast Cancer

Stephen Malamud, MD, associate professor of medicine at the Icahn School of Medicine at Mount Sinai in New York, explains the differences in efficacy for various CDK drugs.

© 2021 /alert® unless otherwise noted. All rights reserved.
Reproduction in whole or in part without permission is prohibited.
Privacy Policy | Terms of Use
Do Not Sell My Personal Information